David Church

Dr. David Church is a researcher at the Centre for Human Genetics, University of Oxford, based at the Henry Wellcome Building of Genomic Medicine. He is affiliated with Brasenose College and collaborates with prominent researchers including Ian Tomlinson and Dr. Claire Palles at Oxford, as well as international collaborators at Leiden University Medical Centre and University of Zurich.

Dr. Church's research focuses on tumor-immune system interactions, particularly in cancers with high mutational loads from polymerase proofreading domain mutations. His work demonstrates that ultramutated POLE-mutant colorectal and endometrial cancers have excellent prognoses due to strong anti-tumor T cell responses against numerous neoantigens. His research spans cancer genomics, immunotherapy mechanisms, and molecular classification of gastrointestinal and gynecological cancers.

Analysis of Dr. Church's publications reveals consistent focus on mismatch repair-deficient and POLE-mutant cancers across multiple tumor types. His work integrates genomic analysis with immune profiling to understand tumor evolution, immune evasion mechanisms, and biomarker development for immunotherapy response. Key themes include molecular classification systems, tumor microenvironment characterization, and the development of precision medicine approaches for cancer treatment.

Dr. Church leads significant collaborative efforts including the RAINBO clinical trial program, which investigates molecular class-directed adjuvant treatment strategies for endometrial cancer through four international clinical trials. His research has direct implications for treatment de-escalation in favorable prognosis subtypes and novel therapeutic approaches for immunotherapy-resistant cancers.